O
Octant Bio
Developing synthetic technology and applying next-generation DNA sequencing, gene synthesis, and gene editing to discover safer, more effective, cheaper drugs
About Octant Bio
Octant Bio is a biotechnology startup that operates in the field of next-generation medicine. The company's primary focus is on developing novel treatments for complex diseases by leveraging the power of synthetic biology and high-throughput chemistry. The company's unique approach involves understanding the biochemical mechanisms that link genetics to diseases, which is often a gap in the current medical field.
Read full description
Octant Bio serves a broad market that includes healthcare providers, research institutions, and pharmaceutical companies. The company's business model revolves around the development and commercialization of its proprietary technologies. These include engineered genes, reporters, genetic circuits, and human cell lines, all designed and built using their world-class synthetic biology capabilities.
In addition, the company uses nanomole-scale chemical synthesis to explore and subtly tune the chemical space. This process involves combining custom-designed chemical cores with tens of thousands of fragments. The company's multiplexed assay platform allows for massively parallel high-throughput drug discovery. This means that they can test thousands of genetic and chemical inputs to generate millions of biological outputs in human cells.
Octant Bio's operations are further enhanced by advanced statistical and machine learning tools. These tools enable the company to process and accelerate their work, using the most advanced bioinformatics and software techniques.
In terms of revenue generation, Octant Bio likely makes money by licensing its technologies to other companies, selling its products, and providing services related to its expertise.
At a glance
- Status
- Operational
- Founded
- 2017
- Headquarters
- Emeryville, United States
- Employees
- 70
- Open positions
- None listed
- Dealroom signal
- 70.9/100
- Industry
- Health
- Sub-industry
- BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Drug Development, DNA, Genetics and genomics, Synthetic Biology, Spinout, Genome Engineering, Biotech and Pharma, DT and LS
- Technology
- Deep Tech
- Business model
- Manufacturing
- Client focus
- b2b
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES BOther financing | Apr 2022 | $80M | $320M | Catalio Capital Management · Andreessen Horowitz · Allen & Company · Bristol-Myers Squibb | ↗ |
| SERIES AOther financing | May 2020 | $30M | $120M | Andreessen Horowitz | ↗ |
Growth signals
Latest recorded traffic for Octant Bio is 12K monthly website visits, up 55.8% over the last three months. Octant Bio's team grew 0% over the past year.
Open positions
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed9 investors entered at this stage
Lux Capital
SV Angel
Lars Fjeldsoe-Nielsen
Ulu Ventures
Refactor Capital
Balderton Capital
Fifty Years
Catapult VC
+ND Capital
Series A4 investors entered at this stage
Andreessen Horowitz
Catalio Capital Management
Allen & Company
Bristol-Myers Squibb
Other known investors1 additional known investor
University of California, Los Angeles
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Octant Bio on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Octant Bio’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.